Literature DB >> 32807635

Pre-existing diabetes is worse for SARS-CoV-2 infection; an endothelial perspective.

Lucia La Sala1, Livio Luzi2, Antonio E Pontiroli3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32807635      PMCID: PMC7346795          DOI: 10.1016/j.numecd.2020.07.007

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


× No keyword cloud information.
Sir, We read with great interest the meta-analysis by Mantovani et colleagues [1] showing a greater risk of severe/critical illness and in-hospital mortality associated with COVID-19 (Coronavirus Disease-19) in patients with diabetes. Covid-19 is caused by the beta-type coronavirus SARS-CoV-2, highly virulent for its ability to infect with high affinity human cells. It is possible that severe and fatal infections with COVID-19 occur more in subjects with impaired immune system, such as in diabetic patients, the elderly or in patients with cardiovascular diseases (CVD, in particular hypertension), involving multi-organ damage, particularly the cardiovascular system. The pathogenic mechanism of COVID-19 is far from being understood, but recent evidence suggests that the severity of SARS-CoV-2 infection is attributable, rather than to the virus itself, to the pro-inflammatory cytokine storm and to exaggerated systemic inflammation [2], that triggers abnormal activation of the coagulation cascade and thrombotic states [3]. The incidence of thrombotic phenomena in patients admitted to intensive care units (ICU) is high: about 31% of 184 patients with COVID-19 pneumonia showed thrombotic complications [4,5]. Among in-patients with COVID-19, diabetes and/or hyperglycemia occurred frequently, and glycemic control is of prognostic value in diabetic in-patients [6]. The relationship between hyperglycemia and activation of the coagulation system has been associated in patients with diabetes mellitus [7,8]; more than half of the mortality in diabetes is related to CVD, and the increased risk is related to glycemic control; It is known that hyperglycemia causes endothelial damage, a hallmark of coagulation dysfunction. It is possible that the development of endothelial dysfunction, combined with platelet resistance to anti-aggregatory effects, leads to loss of control over platelet activation. Therefore, the virus infection seems to enhance the pre-existing endothelial damage and metabolic derangements typical of diabetes that, coupled to increased pro-thrombotic cytokines such as interferon-γ (IFNγ), interleukin (IL)-6, IL-17, IL-9, IL-1β, chemokine-ligand-2 (CCL2) and TGFβ [9], with a more deleterious effects, influencing the endothelial activation towards an up-regulation of coagulation factors, the anti-thrombin glycosylation and enhancing thrombosis. Endothelial dysfunction is associated with several vascular conditions leading to multi-organ failure, and the severity of COVID-19 could be exacerbated in all manifestations of endothelial injury. The critical processes responsible for endothelial injury could be explained by the activation of signalling pathways, as 1) transcription factor nuclear factor kB (NF-kB) known mediator of inflammation, 2) molecules such as advanced glycated end products (AGEs), able to modify the components of the extracellular matrix (ECM), 3) changes in nitric oxide (NO) bioavailability and abnormalities of vascular permeability, that may favor inflammatory responses and the alteration in hemodynamics and shear stress. We suggest that pre-existing diabetes could contribute to increased severity of COVID-19 by exaggerated pro-inflammatory response at the endothelial level; elevated glucose and oxidative lipids might also contribute to enhancing thrombotic phenomena and severity of infection.

Funding information

This work was supported by IRCCS MultiMedica, Milan, Italy, by , Milan, Italy, and by a Grant "Ricerca Corrente"; to IRCCS Istituto MultiMedica from , Italy.

Declaration of Competing Interest

The authors have no conflict of interests with the contents of this letter.
  9 in total

1.  The link between diabetes and atherosclerosis.

Authors:  Lucia La Sala; Francesco Prattichizzo; Antonio Ceriello
Journal:  Eur J Prev Cardiol       Date:  2019-11-13       Impact factor: 7.804

2.  Venous thrombosis is associated with hyperglycemia at diagnosis: a case-control study.

Authors:  J Hermanides; D M Cohn; J H Devries; P W Kamphuisen; R Huijgen; J C M Meijers; J B L Hoekstra; H R Büller
Journal:  J Thromb Haemost       Date:  2009-05-04       Impact factor: 5.824

3.  Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.

Authors:  Huan Han; Lan Yang; Rui Liu; Fang Liu; Kai-Lang Wu; Jie Li; Xing-Hui Liu; Cheng-Liang Zhu
Journal:  Clin Chem Lab Med       Date:  2020-06-25       Impact factor: 3.694

4.  Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies.

Authors:  Alessandro Mantovani; Christopher D Byrne; Ming-Hua Zheng; Giovanni Targher
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-05-29       Impact factor: 4.222

5.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.

Authors:  Lihua Zhu; Zhi-Gang She; Xu Cheng; Juan-Juan Qin; Xiao-Jing Zhang; Jingjing Cai; Fang Lei; Haitao Wang; Jing Xie; Wenxin Wang; Haomiao Li; Peng Zhang; Xiaohui Song; Xi Chen; Mei Xiang; Chaozheng Zhang; Liangjie Bai; Da Xiang; Ming-Ming Chen; Yanqiong Liu; Youqin Yan; Mingyu Liu; Weiming Mao; Jinjing Zou; Liming Liu; Guohua Chen; Pengcheng Luo; Bing Xiao; Changjiang Zhang; Zixiong Zhang; Zhigang Lu; Junhai Wang; Haofeng Lu; Xigang Xia; Daihong Wang; Xiaofeng Liao; Gang Peng; Ping Ye; Jun Yang; Yufeng Yuan; Xiaodong Huang; Jiao Guo; Bing-Hong Zhang; Hongliang Li
Journal:  Cell Metab       Date:  2020-05-01       Impact factor: 27.287

6.  COVID-19: immunopathology and its implications for therapy.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2020-05       Impact factor: 53.106

7.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.

Authors:  Tomasz J Guzik; Saidi A Mohiddin; Anthony Dimarco; Vimal Patel; Kostas Savvatis; Federica M Marelli-Berg; Meena S Madhur; Maciej Tomaszewski; Pasquale Maffia; Fulvio D'Acquisto; Stuart A Nicklin; Ali J Marian; Ryszard Nosalski; Eleanor C Murray; Bartlomiej Guzik; Colin Berry; Rhian M Touyz; Reinhold Kreutz; Dao Wen Wang; David Bhella; Orlando Sagliocco; Filippo Crea; Emma C Thomson; Iain B McInnes
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

8.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

9.  Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.

Authors:  Marisa Dolhnikoff; Amaro Nunes Duarte-Neto; Renata Aparecida de Almeida Monteiro; Luiz Fernando Ferraz da Silva; Ellen Pierre de Oliveira; Paulo Hilário Nascimento Saldiva; Thais Mauad; Elnara Marcia Negri
Journal:  J Thromb Haemost       Date:  2020-06       Impact factor: 16.036

  9 in total
  1 in total

1.  Comorbidities and laboratory parameters associated with SARS-CoV-2 infection severity in patients from the southeast of Mexico: a cross-sectional study.

Authors:  Eduardo De la Cruz-Cano; Cristina Del C Jiménez-González; José A Díaz-Gandarilla; Carlos J López-Victorio; Adelma Escobar-Ramírez; Sheila A Uribe-López; Elizabeth Huerta-García; Jorge-Tonatiuh Ayala-Sumuano; Vicente Morales-García; Liliana Gútierrez-López; José A González-Garrido
Journal:  F1000Res       Date:  2022-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.